Literature DB >> 11030354

Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization.

J Schlessinger1, A N Plotnikov, O A Ibrahimi, A V Eliseenkova, B K Yeh, A Yayon, R J Linhardt, M Mohammadi.   

Abstract

The crystal structure of a dimeric 2:2:2 FGF:FGFR:heparin ternary complex at 3 A resolution has been determined. Within each 1:1 FGF:FGFR complex, heparin makes numerous contacts with both FGF and FGFR, thereby augmenting FGF-FGFR binding. Heparin also interacts with FGFR in the adjoining 1:1 FGF:FGFR complex to promote FGFR dimerization. The 6-O-sulfate group of heparin plays a pivotal role in mediating both interactions. The unexpected stoichiometry of heparin binding in the structure led us to propose a revised model for FGFR dimerization. Biochemical data in support of this model are also presented. This model provides a structural basis for FGFR activation by small molecule heparin analogs and may facilitate the design of heparin mimetics capable of modulating FGF signaling.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11030354     DOI: 10.1016/s1097-2765(00)00073-3

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  367 in total

1.  Heparan sulfate proteoglycans are ligands for receptor protein tyrosine phosphatase sigma.

Authors:  A Radu Aricescu; Iain W McKinnell; Willi Halfter; Andrew W Stoker
Journal:  Mol Cell Biol       Date:  2002-03       Impact factor: 4.272

Review 2.  Heparan sulfate: growth control with a restricted sequence menu.

Authors:  J T Gallagher
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

3.  Oligomerization of acidic fibroblast growth factor is not a prerequisite for its cell proliferation activity.

Authors:  Alphonse I Arunkumar; Thallampuranam Krishnaswamy S Kumar; Karuppanan Muthusamy Kathir; Sampath Srisailam; Han-Min Wang; Philominathan Sagaya Theresa Leena; Ya-Hui Chi; Ho-Chz Chen; Chieh-Hsi Wu; Rong-Tsun Wu; Gu-Gang Chang; Ing-Ming Chiu; Chin Yu
Journal:  Protein Sci       Date:  2002-05       Impact factor: 6.725

Review 4.  Epithelial mesenchymal interactions, the ECM and limb development.

Authors:  Peter Lonai
Journal:  J Anat       Date:  2003-01       Impact factor: 2.610

Review 5.  Fibroblast growth factor receptor 3 mutations in achondroplasia and related forms of dwarfism.

Authors:  William A Horton; Gregory P Lunstrum
Journal:  Rev Endocr Metab Disord       Date:  2002-12       Impact factor: 6.514

6.  Syndecan-syntenin-ALIX regulates the biogenesis of exosomes.

Authors:  Maria Francesca Baietti; Zhe Zhang; Eva Mortier; Aurélie Melchior; Gisèle Degeest; Annelies Geeraerts; Ylva Ivarsson; Fabienne Depoortere; Christien Coomans; Elke Vermeiren; Pascale Zimmermann; Guido David
Journal:  Nat Cell Biol       Date:  2012-06-03       Impact factor: 28.824

7.  Adaptation of tick-borne encephalitis virus to BHK-21 cells results in the formation of multiple heparan sulfate binding sites in the envelope protein and attenuation in vivo.

Authors:  C W Mandl; H Kroschewski; S L Allison; R Kofler; H Holzmann; T Meixner; F X Heinz
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

Review 8.  Insulin and epidermal growth factor receptor family members share parallel activation mechanisms.

Authors:  Kathryn M Ferguson; Chun Hu; Mark A Lemmon
Journal:  Protein Sci       Date:  2020-04-28       Impact factor: 6.725

9.  Gas-Phase Analysis of the Complex of Fibroblast GrowthFactor 1 with Heparan Sulfate: A Traveling Wave Ion Mobility Spectrometry (TWIMS) and Molecular Modeling Study.

Authors:  Yuejie Zhao; Arunima Singh; Yongmei Xu; Chengli Zong; Fuming Zhang; Geert-Jan Boons; Jian Liu; Robert J Linhardt; Robert J Woods; I Jonathan Amster
Journal:  J Am Soc Mass Spectrom       Date:  2016-09-23       Impact factor: 3.109

10.  Synthesis of heparin-like oligosaccharides on polymer supports.

Authors:  Rafael Ojeda; Olimpia Terentí; José-Luis de Paz; Manuel Martín-Lomas
Journal:  Glycoconj J       Date:  2004       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.